Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 11/20 | 0.51 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.49 |
| ▸ | GSK3A | P49840 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | PIM1 | P11309 | 1/20 | 0.47 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.45 |
| ▸ | PRKCA | P17252 | 1/20 | 0.44 |
| ▸ | GSK3B | P49841 | 1/20 | 0.44 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.44 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.44 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.44 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13027606 | 0.86 | IRAK4 (0.58) | CHEK1MAPKAPK2GSK3AMAPTPIM1 | |
| SCHEMBL13027571 | 0.86 | CHEK1 (0.60) | CHEK1MAPKAPK2PIM1PIM3PRKCA | |
| SCHEMBL13028195 | 0.85 | GSK3A (0.44) | GSK3AMAPTPIM1PIM3HDAC1 | |
| SCHEMBL13027615 | 0.84 | PIM1 (0.57) | CHEK1MAPKAPK2GSK3APIM1PIM3 | |
| SCHEMBL11923900 | 0.84 | MAPT (0.55) | CHEK1MAPKAPK2MAPTPIM1PIM3 | |
| SCHEMBL11923983 | 0.83 | MAPKAPK2 (0.48) | CHEK1MAPKAPK2PIM1PIM3 | |
| SCHEMBL13027569 | 0.83 | CHEK1 (0.60) | CHEK1MAPKAPK2PIM1PIM3PRKCA | |
| SCHEMBL11924323 | 0.83 | CHEK1 (0.47) | CHEK1GSK3AMAPTPIM1PIM3 | |
| SCHEMBL11924267 | 0.82 | CHEK1 (0.50) | CHEK1GSK3AMAPTPIM1PIM3 | |
| SCHEMBL13027582 | 0.82 | CHEK1 (0.56) | CHEK1MAPKAPK2PIM1PIM3PRKCA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8293747-B2 | Heterocyclic amide compounds as protein kinase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2012-10-23 | — | — | US | disclosed |
| US-8293747-B2 | Heterocyclic amide compounds as protein kinase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2012-10-23 | — | — | US | disclosed |
| US-20100286135-A1 | HETEROCYCLIC AMIDE COMPOUNDS AS PROTEIN KINASE INHIBITORS | Schering Corporation Patent Department, K-6-1; 1990 (US) | 2010-11-11 | — | — | US | disclosed |
| US-20100286135-A1 | HETEROCYCLIC AMIDE COMPOUNDS AS PROTEIN KINASE INHIBITORS | Schering Corporation Patent Department, K-6-1; 1990 (US) | 2010-11-11 | — | — | US | disclosed |
| WO-2009014637-A2 | HETEROCYCLIC AMIDE COMPOUNDS AS PROTEIN KINASE INHIBITORS | SCHERING CORPORATION (US) | 2009-01-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286135-A1 | HETEROCYCLIC AMIDE COMPOUNDS AS PROTEIN KINASE INHIBITORS | MTOR, CDK1, MAP3K8 | CHEK1 113/4885MAPKAPK2 31/4885GSK3A 218/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.